These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
129 related articles for article (PubMed ID: 2698471)
1. Immunotoxins, ligand-toxin conjugates and molecular targeting. Soria M Pharmacol Res; 1989; 21 Suppl 2():35-46. PubMed ID: 2698471 [TBL] [Abstract][Full Text] [Related]
2. Strategies to Improve the Clinical Utility of Saporin-Based Targeted Toxins. Giansanti F; Flavell DJ; Angelucci F; Fabbrini MS; Ippoliti R Toxins (Basel); 2018 Feb; 10(2):. PubMed ID: 29438358 [TBL] [Abstract][Full Text] [Related]
3. An immunotoxin composed of monoclonal anti-Thy 1.1 antibody and a ribosome-inactivating protein from Saponaria officinalis: potent antitumor effects in vitro and in vivo. Thorpe PE; Brown AN; Bremner JA; Foxwell BM; Stirpe F J Natl Cancer Inst; 1985 Jul; 75(1):151-9. PubMed ID: 3859688 [TBL] [Abstract][Full Text] [Related]
4. Prospects of bacterial and plant protein-based immunotoxins for treatment of cancer. Weidle UH; Tiefenthaler G; Schiller C; Weiss EH; Georges G; Brinkmann U Cancer Genomics Proteomics; 2014; 11(1):25-38. PubMed ID: 24633317 [TBL] [Abstract][Full Text] [Related]
5. Nucleotide sequence of cDNA coding for saporin-6, a type-1 ribosome-inactivating protein from Saponaria officinalis. Benatti L; Saccardo MB; Dani M; Nitti G; Sassano M; Lorenzetti R; Lappi DA; Soria M Eur J Biochem; 1989 Aug; 183(2):465-70. PubMed ID: 2547612 [TBL] [Abstract][Full Text] [Related]
6. Studies on ribosome-inactivating proteins from Saponaria officinalis. Soria MR; Benatti L; Nitti G; Ceriotti A; Solinas M; Lappi DA; Lorenzetti R Targeted Diagn Ther; 1992; 7():193-212. PubMed ID: 1633290 [No Abstract] [Full Text] [Related]
7. Immunotoxins in cancer therapy: Review and update. Akbari B; Farajnia S; Ahdi Khosroshahi S; Safari F; Yousefi M; Dariushnejad H; Rahbarnia L Int Rev Immunol; 2017 Jul; 36(4):207-219. PubMed ID: 28282218 [TBL] [Abstract][Full Text] [Related]
8. Immunotoxins: is there a clinical value? Gottstein C; Winkler U; Bohlen H; Diehl V; Engert A Ann Oncol; 1994; 5 Suppl 1():97-103. PubMed ID: 7826425 [TBL] [Abstract][Full Text] [Related]
10. Immunotoxins and cytokine toxin fusion proteins. Strom TB; Anderson PL; Rubin-Kelley VE; Williams DP; Kiyokawa T; Murphy JR Semin Immunol; 1990 Nov; 2(6):467-79. PubMed ID: 2104283 [TBL] [Abstract][Full Text] [Related]
11. Molecular action of the type 1 ribosome-inactivating protein saporin 5 on Vicia sativa ribosomes. Iglesias R; Arias FJ; Rojo MA; Escarmis C; Ferreras JM; Girbés T FEBS Lett; 1993 Jul; 325(3):291-4. PubMed ID: 8319810 [TBL] [Abstract][Full Text] [Related]
12. The development of immunotoxins for the therapy of cancer, AIDS, and immune dysfunctions. Vitetta ES Princess Takamatsu Symp; 1988; 19():333-40. PubMed ID: 3077626 [TBL] [Abstract][Full Text] [Related]
13. Recombinant targeted proteins for biotherapy. Ahmad A; Law K Mol Biother; 1990 Jun; 2(2):67-73. PubMed ID: 2194500 [TBL] [Abstract][Full Text] [Related]
14. Anti-CD30 (BER=H2) immunotoxins containing the type-1 ribosome-inactivating proteins momordin and PAP-S (pokeweed antiviral protein from seeds) display powerful antitumour activity against CD30+ tumour cells in vitro and in SCID mice. Terenzi A; Bolognesi A; Pasqualucci L; Flenghi L; Pileri S; Stein H; Kadin M; Bigerna B; Polito L; Tazzari PL; Martelli MF; Stirpe F; Falini B Br J Haematol; 1996 Mar; 92(4):872-9. PubMed ID: 8616080 [TBL] [Abstract][Full Text] [Related]
15. Immunotoxins and cancer therapy. Li Z; Yu T; Zhao P; Ma J Cell Mol Immunol; 2005 Apr; 2(2):106-12. PubMed ID: 16191416 [TBL] [Abstract][Full Text] [Related]
16. Comparative cytotoxicity and pharmacokinetics of antimelanoma immunotoxins containing either natural or recombinant gelonin. Rosenblum MG; Marks JW; Cheung LH Cancer Chemother Pharmacol; 1999; 44(4):343-8. PubMed ID: 10447583 [TBL] [Abstract][Full Text] [Related]
17. Immunotoxins: a clinical review of their use in the treatment of malignancies. Hertler AA; Frankel AE J Clin Oncol; 1989 Dec; 7(12):1932-42. PubMed ID: 2685183 [TBL] [Abstract][Full Text] [Related]